Fusen Pharmaceutical Company Limited Announces Approval and Launch of Dydrogesterone Tablet in China

Key Highlights

• Regulatory Approval: Fusen Pharmaceutical’s wholly-owned subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited, has received marketing approval from the National Medical Products Administration (NMPA) of the PRC for its new product, Dydrogesterone Tablet (trademark: Yunmeiyan 孕美顏).
• Therapeutic Indications: The tablet is indicated for treating a wide range of gynecological and reproductive disorders linked to endogenous progesterone deficiency, including dysmenorrhea, endometriosis, secondary amenorrhea, irregular menstrual cycles, dysfunctional uterine bleeding, premenstrual syndrome, threatened or habitual miscarriage, infertility caused by luteal phase deficiency, and for luteal phase support in assisted reproductive technology.
• Product Advantages: Dydrogesterone is a synthetic progestogen with a structure and function similar to natural progesterone, offering higher bioavailability, lower dosing frequency, and improved liver safety compared to natural progesterone. It lacks oestrogenic, androgenic, or corticosteroid effects and does not increase the risk of breast cancer, distinguishing it from traditional synthetic progestogens.
• Guideline Recommendations: The product is classified as a Class B drug under the National Healthcare Security Administration and is recommended by various authoritative PRC medical guidelines for gynecological and obstetric diseases.
• Market Opportunity: In 2025, Dydrogesterone Tablets generated approximately RMB2.5 billion in aggregate sales revenue in urban and county-level public hospitals, as well as urban pharmacies in China, signaling strong market demand and commercial potential.
• Strategic Significance: The approval of Dydrogesterone Tablet significantly strengthens Fusen Pharmaceutical’s product portfolio in the gynecology and reproductive health segment, marking a breakthrough and expanding the company’s therapeutic options for patients.

Investor-Relevant Details

• Pipeline Expansion: This approval adds another important product to Fusen’s pipeline, potentially driving future revenue growth and enhancing its competitive position in the market.
• Market Impact: Given the substantial sales figures cited for the category, entry into this market could result in increased revenue and profitability for the company, which is potentially price-sensitive and may positively affect share valuation.
• Regulatory and Guideline Support: The product’s inclusion in key PRC clinical guidelines and its status as a Class B drug under national healthcare insurance are expected to support adoption and reimbursement, further improving commercialization prospects.
• Safety Profile: The favorable safety, efficacy, and dosing profile of Dydrogesterone compared to both natural and traditional synthetic progestogens may lead to swift uptake among clinicians and patients, supporting market penetration.
• Management Statement: The Board, led by Chairman and CEO Cao Zhiming, underscores the strategic value of the approval, signaling continued focus on innovation and pipeline growth in women’s health.

Shareholder Considerations

• Potential Share Price Catalyst: The approval and launch of a high-demand, guideline-recommended product with strong market sales history can be a material catalyst for share price appreciation, especially given the RMB2.5 billion addressable market.
• Competitive Positioning: The product’s clinical advantages and regulatory support position Fusen Pharmaceutical favorably against competitors in the reproductive health space.
• Strategic Direction: The announcement signals Fusen’s commitment to expanding its gynecology/reproductive pipeline, which may impact investor perception and valuation multiples.

Board and Management

The Board of Directors comprises Chairman and CEO Mr. Cao Zhiming, along with executive directors Mr. Hou Taisheng, Mr. Chi Yongsheng, and Ms. Meng Qingfen, and independent non-executive directors Mr. Lee Kwok Tung Louis, Dr. To Kit Wa, and Mr. Yu Ho Ming.

Conclusion

The approval of Dydrogesterone Tablet represents a significant milestone for Fusen Pharmaceutical, offering substantial commercial opportunity, strengthening the product pipeline, and possibly driving share price performance. Investors should monitor sales progression, market adoption, and regulatory developments as key indicators of impact.

Disclaimer: This article is intended for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult with professional advisors before making any investment decisions. The information provided is based on company disclosures as of 27 April 2026 and may be subject to change.

View FUSEN PHARM Historical chart here